Royal Fund Management, LLC Abb Vie Inc. Call Options Transaction History

Royal Fund Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Oct 08, 2024	BUY	$163.84 - $199.33 $360,448 - $438,526	2,200 New	2,200 $434,000
Q1 2024 Apr 11, 2024	SELL	$159.82 - $182.1 $79,910 - $91,050	-500 Reduced 17.24%	2,400 $437,000
Q4 2023 Feb 06, 2024	BUY	$137.6 - $154.97 $399,040 - $449,413	2,900 New	2,900 $449,000
Q2 2023 Jul 12, 2023	SELL	$132.51 - $164.9 $26,502 - $32,980	-200 Reduced 5.71%	3,300 $444,000
Q1 2023 Apr 10, 2023	SELL	$144.61 - $166.54 $101,227 - $116,578	-700 Reduced 16.67%	3,500 $557,000
Q4 2022 Jan 20, 2023	BUY	$138.31 - $165.87 $580,902 - $696,654	4,200 New	4,200 $0
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $514,721 - $638,625	3,900 New	3,900 $632,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Royal Fund Management, LLC with notifications on news.